Physician profile
Ginger E Smith
NPI 1528029972
$5,187.67
in general payments reported to CMS, 2019-2025
22 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $891 · 2022: $1,618 · 2023: $818 · 2024: $861 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,467 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,467.09 |
| Education | $211.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,386.06 | 2021-2025 | |
| Genzyme Corporation | $633.91 | 2021-2025 | |
| Pfizer INC. | $579.30 | 2021-2025 | |
| Lilly USA, LLC | $557.85 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $434.94 | 2021-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $368.82 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $254.20 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $172.13 | 2021-2025 | Anzupgo, Adbry |
| Novartis Pharmaceuticals Corporation | $150.87 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $100.78 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $98.60 | 2022-2025 | Ilumya |
| Incyte Corporation | $91.83 | 2022-2023 | Opzelura |
| Galderma Laboratories, L.P. | $76.85 | 2021-2025 | Nemluvio |
| Amgen INC. | $58.91 | 2023-2024 | Otezla |
| Dermavant Sciences, INC. | $48.84 | 2023-2024 | Vtama |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $45.17 | 2023 | |
| Almirall LLC | $33.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.21 | 2023 | Cyltezo |
| Organon LLC | $20.23 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.63 | 2021 | |
| Dermira, INC. | $17.26 | 2021 | |
| Allergan, INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.